Table 3.

Outcomes of combination therapies with IFN-free DAAs in patients with HIV/HCV co-infection

Treatment regimen/ study	Type of study	Treatment duration (weeks)	HCV GT	Sample size	SVR rate (%)	SAE rate (%)	Treatment discontinuation rate (%)	Comments
Sofosbuvir/ribavirin
PHOTON-1   Sulkowski et al. [84]	CT	12–24	GT1–3	223	GT1 24 W: 76% (87/114) GT2 12 W: 88% (23/26) GT2 24 W: 92% (22/24) GT3 12 W: 67% (28/42) GT3 24 W: 94% (16/17)	6% (14/223)	3% (7/223)
PHOTON-2   Molina et al. [85]	CT	12–24	GT1–4	274	GT1 24 W: 85% (95/112) GT2 12 W: 89% (17/19) GT2 24 W: 83% (5/6) GT3 24 W: 89% (94/106) GT4 24 W: 84% (26/31)	1% (4/274)	2% (6/274)
Sofosbuvir/ledipasvir								Co-administration of ledipasvir and TDF caused an increase in TDF serum concentration
ERADICATE study   Osinusi et al. [35]	CT	12	GT1	50	98% (49/50)	2% (1/50)	0
ION-4   Naggie et al. [36]	CT	12	GT1/4	335	96% (322/335)	2% (8/335)	0
PTV/RTV/OBV and DSV								Should be monitored for drug–drug interactions with RTV
TURQUOISE-1   Sulkowski et al. [87]	CT	12–24	GT1	63	12 W: 94% (29/31) 24 W: 91% (29/32)	0	0
Elbasvir/grazoprevir
C-EDGE CO-INFECTION   Rockstroh et al. [88]	CT	12	GT1/4/6	218	96% (210/218)	1% (2/218)	0
Sofosbuvir/velpatasvir								Renal function should be monitored in TDF with velpatasvir co-administration
ASTRAL-5   Wyles et al. [107]	CT	12	GT1–4	106	95% (101/106)	2% (2/106)	2% (2/106)
Sofosbuvir/daclatasvir
ALLY-2   Hinestrosa et al. [90]	CT	8-12	GT1–4	203	12 W: 97.4% (149/153) 8 W: 76% (38/50)	2% (4/203)	0

CT clinical trials, RW real-world data, IFN interferon, DAAs direct-acting antivirals, HIV human immunodeficiency virus, HCV hepatitis C virus, 12 W at 12 weeks, 24 W at 24 weeks, GT genotype, SVR sustained viral response, SAE serious adverse event, TDF tenofovir disoproxil fumarate